(SNY) Sanofi BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SNY) Sanofi Complete Analysis Pack
See the Bigger Picture
This Sanofi BCG Matrix is a ready-made strategic analysis used to assess the company’s products or business units across Stars, Cash Cows, Question Marks, and Dogs. What you see on this page is a real preview of the actual report content, so you can review the format and substance before buying. Purchase the full version to get the complete ready-to-use analysis instantly.
Stars
Dupixent, 2017 launch, multi-€bn sales
Dupixent, launched in 2017, is Sanofi's biggest growth engine and its clearest high-share biologic. Sanofi reported 2025 sales above €14bn as Dupixent kept expanding into asthma, atopic dermatitis, COPD and other type 2 inflammatory diseases. That mix of fast growth and leading share fits a classic Star in the BCG matrix.
Beyfortus, 2023 launch, RSV infant prophylaxis
Beyfortus turned into a Star after its 2023 launch, with Sanofi reporting €1.7bn sales in 2024 as RSV infant prophylaxis scaled fast. Demand rose with broader seasonal rollout and pediatric uptake across major markets, and the brand quickly gained strong share in a high-growth category. Early launch momentum and repeat seasonal use support a Star profile.
Altuviiio, 2023 launch, once-weekly factor VIII
ALTUVIIIO, launched in 2023, is Sanofi's hemophilia A growth driver and fits Star status: it targets a premium specialty market and grew fast after launch. Its once-weekly factor VIII dosing cuts treatment from the usual 2-3 infusions a week, a clear clinical edge. High-value pricing and strong uptake support its growth profile.
Tzield, 2022 launch, stage 2 type 1 diabetes
Tzield, launched in 2022, is Sanofi’s first disease-modifying therapy for stage 2 type 1 diabetes and was FDA-approved to delay stage 3 onset by a median 2 years in the pivotal study. The market is still early, but autoantibody screening and referral are widening the diagnosis pool. If access and adoption keep rising, Tzield can remain a Star-type specialty asset.
- First-in-class delay therapy
- Early market, expanding screening
- Upside depends on access and diagnosis
Nexviazyme, 2021 launch, Pompe disease
Nexviazyme, launched in 2021, is a strong Star for Sanofi in Pompe disease: it targets a rare market with limited direct competition and builds on Sanofi’s enzyme-replacement lead. Growth comes mainly from wider diagnosis and switching patients from older therapy, which supports share gains in a niche disease area.
- 2021 launch
- Rare-disease demand
- Limited direct rivals
- Driven by diagnosis and switching
Sanofi’s Star Drugs: Dupixent Leads Growth
Sanofi’s Stars are Dupixent, Beyfortus, ALTUVIIIO, Tzield, and Nexviazyme. Dupixent is the clear anchor, with 2025 sales above €14bn, while Beyfortus reached €1.7bn in 2024 and kept scaling in RSV prevention.
| Brand | 2025/2024 sales | Star signal |
|---|---|---|
| Dupixent | €14bn+ | High share, fast growth |
ALTUVIIIO, Tzield, and Nexviazyme add newer growth from premium rare-disease and specialty markets.
What is included in the product
Detailed Word Document
Sanofi BCG Matrix: clear view of Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
One-page Sanofi BCG Matrix that clarifies portfolio pain points at a glance
Reference Sources
Provides traceable sources that strengthen credibility and speed smarter, lower-risk decisions.
Cash Cows
Lantus, 2000 launch, basal insulin
Lantus, launched in 2000, is Sanofi’s mature basal insulin brand and fits the Cash Cow profile. Global diabetes demand stays large: the IDF estimated 589 million adults lived with diabetes in 2024, so Lantus still throws off steady cash flow even as growth stays low. Its long market history and meaningful share in a slow insulin market keep it a reliable profit engine.
Toujeo, 2015 launch, premium basal insulin
Toujeo, launched in 2015, is a premium basal insulin with a large installed base and long prescriber history. Its market is mature, so Sanofi can keep promotion lighter than for growth brands and still defend share. That makes Toujeo a steady cash cow: low-growth, durable demand, and reliable contribution to Sanofi’s diabetes earnings.
Fluzone High-Dose, seasonal influenza vaccine
Fluzone High-Dose is a recurring flu-season franchise, so sales repeat each year with vaccine cycles, not category growth. It targets adults 65+, a group that accounts for about 80% of U.S. flu-related deaths, which keeps demand steady and defensible. In Sanofi BCG terms, its high U.S. share and predictable seasonality make it a classic cash cow.
Cablivi, 2018 launch, TTP therapy
Cablivi, launched in 2018, has a strong niche in thrombotic thrombocytopenic purpura (TTP), a rare disease with limited patient volume. That makes it a classic Cash Cow in Sanofi's BCG mix: steady demand, low growth, and little need for heavy expansion spend.
- 2018 launch
- Rare TTP franchise
- Small, mature market
- Stable niche cash flow
Hexaxim and Pentaxim, pediatric combination vaccines
Hexaxim and Pentaxim stay cash cows for Sanofi because pediatric routine immunization creates steady, procurement-led demand, not hype-led growth. WHO data still show about 84% global DTP3 coverage in 2024, and that recurring vaccination need supports stable volumes across public tenders. Their long market history and wide distribution in many countries keep sales resilient even when growth is modest.
- Routine immunization drives repeat demand.
- Public procurement keeps volumes stable.
- Strong market position supports cash flow.
Sanofi’s Cash Cows Keep the Revenue Engine Running
Sanofi’s Cash Cows are mature, high-share brands that still generate steady cash flow in low-growth markets. Lantus and Toujeo remain anchor products in insulin, while Fluzone High-Dose benefits from repeat flu-season demand and Cablivi and Hexaxim/Pentaxim add durable niche and procurement-led revenue.
| Brand | Cash cow driver |
|---|---|
| Lantus | Mature insulin, stable demand |
| Fluzone High-Dose | Recurring flu-season sales |
| Cablivi | Rare-disease niche |
Get Your Copy
Sanofi Reference Sources
The Sanofi BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo pages, no watermarks—just the complete, professionally formatted report ready for immediate use. Once purchased, you’ll get the full file for download, with the same content shown in this preview.
Dogs
Aubagio, 2012 launch, MS oral therapy
Aubagio, launched in 2012 as Sanofi’s oral MS therapy, now fits Dog territory: generic erosion has weakened pricing and share, while the MS market has slowed. The brand has lost its former growth profile, and Sanofi’s 2024 reporting showed continued pressure on legacy MS assets as volume shifted to cheaper rivals.
Kevzara, 2017 launch, rheumatoid arthritis
Kevzara, launched in 2017 for rheumatoid arthritis, remains a small player in a crowded IL-6 and RA biologics market led by much larger brands. Sanofi has reported only modest uptake, with Kevzara delivering low single-digit growth and limited share versus entrenched rivals like Actemra and Humira-class therapies. That weak scale and muted momentum fit the Dog quadrant in Sanofi’s BCG Matrix.
Praluent, 2015 launch, PCSK9 inhibitor
Praluent, launched in 2015, entered the LDL-lowering PCSK9 market where Repatha and Leqvio now set the pace. The class is still niche, with PCSK9 sales dominated by Amgen's Repatha at about $2bn in 2024, while Praluent has stayed well behind. Low share, slow growth, and weak pricing power make Praluent a Dog in Sanofi's BCG matrix.
Multaq, 2009 launch, antiarrhythmic
Multaq, launched in 2009, is now a 16-year-old antiarrhythmic in a mature atrial fibrillation market. Generic pressure and slow category growth cap its upside, so it fits Sanofi’s Dogs: low strategic value and weak reinvestment logic versus newer specialty assets like Dupixent, which already tops €13 billion in annual sales.
- 2009 launch; mature asset
- Generic erosion limits value
- Far smaller upside than specialty drugs
Admelog, 2017 launch, rapid-acting insulin
Admelog, launched in 2017, is a rapid-acting insulin in a crowded market with Humalog, NovoLog, Fiasp, and Lyumjev. That keeps pricing under pressure and caps share gains, so it fits Sanofi’s maintenance bucket more than a true leader. The brand helps defend Sanofi’s insulin base, but it is not a growth engine.
- 2017 launch
- Crowded rapid-acting insulin field
- Price pressure limits growth
- Maintenance role, not share leader
Sanofi’s Aging “Dog” Brands Face Erosion as Dupixent Leads
Sanofi’s Dogs are aging, low-share brands with weak pricing power and little growth upside. Aubagio, Kevzara, Praluent, Multaq, and Admelog all face generic or crowded-market pressure, so they are more maintenance assets than growth drivers. They trail Sanofi’s 2024-25 winners like Dupixent, which topped €13 billion in annual sales.
| Brand | Dog signal |
|---|---|
| Aubagio | Generic erosion |
| Kevzara | Low share |
| Praluent | Weak scale |
| Multaq | Mature market |
| Admelog | Price pressure |
Question Marks
Sarclisa, 2019 launch, multiple myeloma
Sarclisa, launched in 2019, is aimed at multiple myeloma, a large oncology field that keeps growing as patients live longer and treatment lines expand. In 2024, Sarclisa sales reached about €1.1 billion, but it still trails dominant franchises like Johnson & Johnson's Darzalex, which generated about $11.7 billion. That mix of high growth and lower share makes Sarclisa a clear Question Mark for Sanofi.
Rilzabrutinib, late-stage BTK inhibitor
Rilzabrutinib is Sanofi’s late-stage BTK inhibitor in phase 3 across several immune-mediated diseases, including immune thrombocytopenia and chronic spontaneous urticaria. The addressable markets are large, but it has no commercial sales or share yet, so it still sits in the Question Marks bucket. Sanofi will need heavy R&D spend and clean late-stage data to prove it can earn a Star position.
Frexalimab, late-stage anti-CD40L
Frexalimab is Sanofi’s late-stage anti-CD40L antibody for multiple sclerosis and other autoimmune diseases. Multiple sclerosis affects nearly 3 million people worldwide, so the addressable market is large and still growing, but it is crowded with Roche, Novartis, and Bristol Myers Squibb therapies. With no approved launch or revenue scale yet, frexalimab stays a Question Mark.
Amlitelimab, late-stage OX40L antibody
Amlitelimab is still a pre-revenue late-stage OX40L antibody, so Sanofi has no market share yet in atopic dermatitis, a global market affecting about 200 million people and still growing. That makes it a classic BCG Question Mark: big upside, but no proof of commercial pull. If phase 3 data or launch uptake lag, it stays an invest-or-exit asset.
- Big market, no sales yet
- Atopic dermatitis: ~200M patients
- High upside, high execution risk
Itepekimab, late-stage IL-33 antibody
Itepekimab is a late-stage IL-33 antibody for COPD and asthma, two very large respiratory immunology markets with major unmet need. COPD affects about 390 million people worldwide, and asthma about 260 million, but Sanofi’s commercial share in this program is still zero because it is not yet approved.
- Late-stage asset
- COPD and asthma focus
- Large unmet-need market
- Zero current sales
Sanofi’s Growth Bets: Big Markets, Early-Stage Risks
Sanofi’s Question Marks are growth assets with no durable share yet: Sarclisa reached about €1.1 billion in 2024, while rilzabrutinib, frexalimab, amlitelimab, and itepekimab are still pre-launch or late-stage, so revenue is zero. Their target markets are large, including multiple myeloma, atopic dermatitis, COPD, and asthma, but each program still needs phase 3 proof and launch uptake to move toward Star status.
| Asset | 2024-2025 status | Why Question Mark |
|---|---|---|
| Sarclisa | €1.1bn sales | High growth, low share |
| Rilzabrutinib | Phase 3 | No sales yet |
| Frexalimab | Late-stage | No sales yet |
| Amlitelimab | Late-stage | No sales yet |
| Itepekimab | Late-stage | No sales yet |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.